Fig. 3

(a) Rates of ≥50% migraine response by 12-week dosing interval and (b) cumulative 4-week intervals with ≥50% migraine response (efficacy population). *P < 0.001 vs placebo. †Nominal P < 0.001 vs placebo (analyses of migraine responder rates over weeks 13–24 were not formally tested per the predefined statistical hierarchy)